Gain Therapeutics, Inc. (GANX) News
Follow Gain Therapeutics, Inc. (GANX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Gain names Gene Mack interim CFO as Gianluca Fuggetta to resign
Gain appointed Gene Mack as interim Chief Financial Officer effective October 1, 2026, after Gianluca Fuggetta notified the company he will resign as principal financial officer effective September 30, 2026.Original SEC
REGULATION | Sep 28, 2026, 08:36 PM UTC
L
GANX - Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
GANX - Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
NEWS | Sep 17, 2026, 11:00 AM UTC
L
Gain Therapeutics (GANX) to Participate in H.C. Wainwright Conference
Gain Therapeutics (GANX) says it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Aug 25, 2026, 11:00 AM UTC
L
GANX gain Therapeutics CEO Gene mack issues letter to shareholders and provides operational update Gain Therapeutics - to commence phase 2 s
GANX gain Therapeutics CEO Gene mack issues letter to shareholders and provides operational update Gain Therapeutics - to commence phase 2 study of rexaceract in Q3 2026
EQUITY | Jul 16, 2026, 11:00 AM UTC
L
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ: GANX ) with a Buy and maintains $8 price target.
EQUITY | Jul 01, 2026, 11:46 AM UTC
H
Gain Therapeutics Obtains FDA Clearance Of IND To Advance GT-02287 Into Phase 2 Clinical Development for Parkinson’s Disease; IND Authorizat
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and people
EARNINGS | Jun 29, 2026, 08:08 PM UTC